[1] Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period. Medicine (Baltimore) 2003;82:299–308. https://doi.org/10.1097/01.md.0000091181.93122.55.
[2] Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248–54. https://doi.org/10.1093/ndt/gfs073.
[3] Sule S, Fivush B, Neu A, Furth S. Increased hospitalizations and death in patients with ESRD secondary to lupus. Lupus 2012;21:1208–13. https://doi.org/10.1177/0961203312451506.
[4] Sule S, Rosen A, Petri M, Akhter E, Andrade F. Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells. PLoS One 2011;6:e17495. https://doi.org/10.1371/journal.pone.0017495.
[5] Krane NK, Burjak K, Archie M, O’donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 1999;33:872–9. https://doi.org/10.1016/s0272-6386(99)70419-1.
[6] Broder A, Khattri S, Patel R, Putterman C. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol 2011;38:2382–9. https://doi.org/10.3899/jrheum.110571.
[7] Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK, et al. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J 2004;45:199–206. https://doi.org/10.3349/ymj.2004.45.2.199.
[8] Stone JH. End-stage renal disease in lupus: Disease activity, dialysis, and the outcome of transplantation. Lupus 1998;7:654–9. https://doi.org/10.1191/096120398678920811.
[9] Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic Lupus Erythematosus in Patients with End-Stage Renal Disease: Long-Term Follow-Up on the Prognosis of Patients and the Evolution of Lupus Activity. Am J Kidney Dis 1990;16:189–95. https://doi.org/10.1016/S0272-6386(12)81017-1.
[10] Coplon N, Siegel R, Fries J. Hemodialysis on end-stage lupus nephritis. Trans Am Soc Artif Intern Organs 1973;19:302–4. https://doi.org/10.1097/00002480-197301900-00050.
[11] Coplon NS, Diskin CJ, Petersen J, Swenson RS. The Long-Term Clinical Course of Systemic Lupus Erythematosus in End-Stage Renal Disease. N Engl J Med 1983;308:186–90. https://doi.org/10.1056/NEJM198301273080403.
[12] Rodby RA, Korbet SM, Lewis EJ. Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis. Am J Med 1987;83:613–8. https://doi.org/10.1016/0002-9343(87)90888-6.
[13] Bruce IN, Hallett DC, Gladman DD, Urowitz MB. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol 1999;26:1490–4.
[14] Stock GG, Krane NK. Treatment of end-stage renal disease due to lupus nephritis: comparison of six patients treated with both peritoneal and hemodialysis. Adv Perit Dial 1993;9:147–51.
[15] Pahl M V., Vaziri ND, Saiki JK, Upham T, Ness R. Chronic Hemodialysis in End‐Stage Lupus Nephritis: Changes of Clinical and Serological Activities. Artif Organs 1984;8:423–8. https://doi.org/10.1111/j.1525-1594.1984.tb04318.x.
[16] Mattos P, Santiago MB. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol. 2012;31(6):897-905. doi:10.1007/s10067-012-1957-9
[17] Okano K, Yumura W, Nitta K, et al. Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med. 2001;40(7):598-602. doi:10.2169/internalmedicine.40.598
[18] Fries JF, Powers R, Kempson RL. Late-stage lupus nephropathy. J Rheumatol 1974;1:166–75.
[19] Kimberly RP, Lockshin MD, Sherman RL, Beary JF, Mouradian J, Cheigh JS. End-stage lupus nephritis: Clinical course to and outcome on dialysis: Experience with 39 patients. Med (United States) 1981;60:277–87. https://doi.org/10.1097/00005792-198107000-00003.
[20] Correia P, Cameron JS, Ogg CS, Williams DG, Bewick M, Hicks JA. End-stage renal failure in systemic lupus erythematosus with nephritis. Clin Nephrol 1984;22:293–302.
[21] Sires RL, Adler SG, Louie JS, Cohen AH. Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares. Am J Nephrol 1989;9:279–84. https://doi.org/10.1159/000167981.
[22] Szeto CC, Li PKT, Wong TYH, Leung CB, Lui SF. Factors associated with active systemic lupus erythematosus after endstage renal disease. J Rheumatol 1998;25:1520–5.
[23] Ribeiro FM, Leite MAP, Velarde GC, Fabris CL, Santos RC, Lugon JR. Activity of systemic lupus erythematosus in end-stage renal disease patients: Study in a Brazilian cohort. Am J Nephrol 2005;25:596–603. https://doi.org/10.1159/000089708.
[24] Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. The Dutch Working Party on Systemic Lupus Erythematosus. Ann Intern Med. 1991;114(3):183-188. doi:10.7326/0003-4819-114-3-183
[25] González-Pulido C, Croca S, Abrol E, Isenberg DA. Long-term activity index after renal failure in a cohort of 32 patients with lupus nephritis. Clin Exp Rheumatol. 2014;32(3):301-307.
[26] Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82. https://doi.org/10.1136/annrheumdis-2012-201940.
[27] Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797–808. https://doi.org/10.1002/acr.21664.
[28] Honda S, Katsumata Y, Karasawa K, Yamanaka H, Harigai M. Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases. JMA J. 2020;3(1):20-28.
[29] Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010;69:20–8. https://doi.org/10.1136/ard.2008.101766.
[30] Fessler BJ, Alarcón GS, McGwin G, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473–80. https://doi.org/10.1002/art.21039.
[31] Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998;7:80–5. https://doi.org/10.1191/096120398678919778.
[32] Ramos-casals ASM, Bove A, Soria N, Muñoz S, Testi A, Plaza J, et al. Previous antímalarial therapy in patients diagnosed with lupus nephritis : Influence on outcomes and survival. Lupus 2008;17:281–8. https://doi.org/10.1177/0961203307086503.
[33] Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60. https://doi.org/10.1001/jamaophthalmol.2014.3459.
[34] Montefiore Medical Center. n.d. https://www.montefiore.org (accessed March 15, 2020).
[35] Bellin E, Fletcher DD, Geberer N, Islam S, Srivastava N. Democratizing information creation from health care data for quality improvement, research, and education-The montefiore medical center experience. Acad Med 2010;85:1362–8. https://doi.org/10.1097/ACM.0b013e3181df0f3b.
[36] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. https://doi.org/10.1002/art.1780400928.
[37] Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7. https://doi.org/10.1002/art.1780251101.
[38] Petri M, Orbai AM, Alarcõn GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86. https://doi.org/10.1002/art.34473.
[39] Jarrett MP, Santhanam S, Del Greco F. The Clinical Course of End-Stage Renal Disease in Systemic Lupus Erythematosus. Arch Intern Med 1983;143:1353–6. https://doi.org/10.1001/archinte.1983.00350070073014.
[40] Marmor MF, Kellner U, Lai TYY , et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016:123:138694. doi:10.1016/j.ophtha.2016.01.058
[41] Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases 2020;79:713-723.
[42] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291